serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma血清促炎介质在不同时期的治疗多发性骨髓瘤患者.pdf

Mediators of Inflammation • 2005:3 (2005) 171–174 • PII: S0962935105412235 • DOI: 10.1155/MI.2005.171 SHORT COMMUNICATION Serum Proinflammatory Mediators at Different Periods of Therapy in Patients With Multiple Myeloma Irfan Kuku,1 Mehmet Refik Bayraktar,2 Emin Kaya,1 Mehmet Ali Erkurt,1 Nihayet Bayraktar,3 Kerim Cıkım,1 and Ismet Aydogdu1 1Department of Hematology, Medical Faculty, Turgut Ozal Medical Center, Inonu University, 44069 Malatya, Turkey 2Department of Medical Microbiology, Medical Faculty, Turgut Ozal Medical Center, Inonu University, 44069 Malatya, Turkey 3Department of Clinical Biochemistry, Medical Faculty, Turgut Ozal Medical Center, Inonu University, 44069 Malatya, Turkey Received 22 December 2004; accepted 1 March 2005 Multiple myeloma (MM) is a malignant disease characterized by the clonal proliferation of plasma cells within the bone marrow. Several cytokines have been demonstrated to be involved in the control of growth, progression, and dissemination of MM. We de- termined serum levels of interleukin-1β (IL-1β ), soluble interleukin-2 receptor (sIL-2R), interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), and C-reactive protein (CRP) in 14 newly diagnosed MM patients. The median age of the patients was 63.4 ± 10.8 years and all of the patients were stage III (classified according to the Durie-Salmon classification). The same pa- rameters were measured in 15 healthy controls. In addition, we also examined the effects of vincristine-adriamycin-dexamethasone (VAD) therapy on the same parameters and mediators as well as the relationship among the parameters in the same patient groups. The serum concentrations of TNF-α, IL-1β, sIL-2R, IL-6, IL-8,